Public Employees Retirement Association of Colorado lowered its holdings in shares of Cambrex Co. (NYSE:CBM) by 98.6% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 6,341 shares of the biotechnology company’s stock after selling 438,964 shares during the period. Public Employees Retirement Association of Colorado’s holdings in Cambrex were worth $377,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Marshall Wace LLP purchased a new stake in shares of Cambrex during the first quarter worth about $30,000. Quantamental Technologies LLC purchased a new stake in shares of Cambrex during the second quarter worth about $100,000. Tower Research Capital LLC TRC grew its position in shares of Cambrex by 67.7% during the second quarter. Tower Research Capital LLC TRC now owns 2,188 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 883 shares in the last quarter. Magnus Financial Group LLC purchased a new stake in shares of Cambrex during the second quarter worth about $215,000. Finally, Panagora Asset Management Inc. grew its position in shares of Cambrex by 205.9% during the second quarter. Panagora Asset Management Inc. now owns 4,894 shares of the biotechnology company’s stock worth $229,000 after purchasing an additional 3,294 shares in the last quarter.
Several analysts recently issued reports on CBM shares. Craig Hallum cut Cambrex from a “buy” rating to a “hold” rating and set a $60.00 target price for the company. in a research report on Monday, August 12th. Zacks Investment Research cut Cambrex from a “buy” rating to a “hold” rating in a report on Tuesday, October 29th. ValuEngine cut Cambrex from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, William Blair cut Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 price target for the company. in a report on Wednesday, August 7th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Cambrex presently has an average rating of “Hold” and a consensus price target of $54.83.
Shares of Cambrex stock traded up $0.01 on Wednesday, reaching $59.86. The company had a trading volume of 365,210 shares, compared to its average volume of 430,197. The firm has a market cap of $2.02 billion, a price-to-earnings ratio of 21.61, a P/E/G ratio of 4.67 and a beta of 2.17. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.37 and a quick ratio of 1.70. The firm’s 50-day moving average price is $59.66 and its two-hundred day moving average price is $51.36. Cambrex Co. has a 1 year low of $33.80 and a 1 year high of $60.29.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Featured Article: Understanding debt-to-equity ratio in fundamental analysis
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.